Company on Schedule to Commence Trial Late This YearVANCOUVER and MINNEAPOLIS - (NewMediaWire) - September 16, 2021 - Neovasc Inc. (Neovasc or the Company) (Nasdaq, TSX: NVCN) announced today that it has received FDA approval for the Investigational Device Exemption (IDE) regarding the COSIRA-II IDE...
Read MoreVANCOUVER and MINNEAPOLIS - (New Media Wire) - August 30, 2021 - Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced that its management team will be participating in the 23rd Annual H.C. Wainwright Global Investment Conference to be held September 13-15, 2021....
Read MoreVANCOUVER and MINNEAPOLIS- (NewMediaWire) - August 17, 2021 - Neovasc Inc. (Neovasc or the Company) (Nasdaq, TSX: NVCN) announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA). Following multiple productive...
Read MoreVANCOUVER and MINNEAPOLIS - (NewMediaWire) - August 10, 2021 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the second quarter ended June 30, 2021.Second Quarter HighlightsGenerated revenue of approximately $633,000 in the quarter, up 123% from the...
Read MoreVANCOUVER - (NewMediaWire) - July 27, 2021 - Neovasc Inc. (NASDAQ,TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021. Neovasc's President and Chief Executive Officer, Fred Colen, and Chris Clark, Chief Financial Officer, will host...
Read MoreNeovasc Team Grows with Addition of Industry Veterans Lisa Becker as VP, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as VP of Clinical AffairsVANCOUVER and MINNEAPOLIS - (NewMediaWire) - July 13, 2021 - Neovasc Inc. (Neovasc or the Company) (Nasdaq, TSX: NVCN) announced today...
Read MoreVANCOUVER and MINNEAPOLIS - (NewMediaWire) - June 18, 2021 - Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study in the International...
Read MoreVANCOUVER and MINNEAPOLIS - June 10, 2021 -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its cash runaway well into 2024, focusing investments on near term...
Read More